Federated Hermes Inc. Boosts Stake in UiPath Inc. (NYSE:PATH)

Federated Hermes Inc. grew its holdings in shares of UiPath Inc. (NYSE:PATH - Free Report) by 857.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 458,126 shares of the healthcare company's stock after purchasing an additional 410,288 shares during the period. Federated Hermes Inc. owned approximately 0.08% of UiPath worth $11,380,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Daiwa Securities Group Inc. boosted its position in UiPath by 9.5% during the 4th quarter. Daiwa Securities Group Inc. now owns 24,100 shares of the healthcare company's stock worth $599,000 after acquiring an additional 2,100 shares during the period. Rakuten Securities Inc. bought a new position in shares of UiPath in the 4th quarter valued at approximately $80,000. SVB Wealth LLC grew its holdings in UiPath by 95.4% in the 4th quarter. SVB Wealth LLC now owns 59,216 shares of the healthcare company's stock valued at $1,471,000 after buying an additional 28,910 shares during the last quarter. Mackenzie Financial Corp grew its holdings in UiPath by 2.9% in the 4th quarter. Mackenzie Financial Corp now owns 151,535 shares of the healthcare company's stock valued at $3,764,000 after buying an additional 4,267 shares during the last quarter. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in shares of UiPath during the 4th quarter worth approximately $223,000. Institutional investors own 62.50% of the company's stock.

Analyst Ratings Changes

PATH has been the topic of several recent analyst reports. Mizuho boosted their price target on UiPath from $22.00 to $25.00 and gave the company a "neutral" rating in a research note on Thursday, March 14th. TD Cowen upped their price objective on UiPath from $25.00 to $28.00 and gave the company an "outperform" rating in a report on Thursday, March 14th. Evercore ISI upped their price objective on UiPath from $24.00 to $27.00 and gave the company an "in-line" rating in a report on Thursday, March 14th. Canaccord Genuity Group boosted their target price on UiPath from $27.00 to $30.00 and gave the company a "buy" rating in a research note on Friday, March 15th. Finally, Royal Bank of Canada reissued a "sector perform" rating and issued a $29.00 target price on shares of UiPath in a research note on Monday, April 1st. Nine research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $27.41.

UiPath Stock Up 0.8 %

Shares of PATH traded up $0.15 during trading hours on Wednesday, hitting $19.70. 6,150,804 shares of the company were exchanged, compared to its average volume of 8,797,234. The company has a market cap of $11.21 billion, a price-to-earnings ratio of -115.58 and a beta of 0.96. UiPath Inc. has a fifty-two week low of $12.38 and a fifty-two week high of $27.87. The firm's fifty day moving average is $22.55 and its 200 day moving average is $21.56.

UiPath (NYSE:PATH - Get Free Report) last released its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The company had revenue of $405.25 million for the quarter, compared to analyst estimates of $383.32 million. Analysts anticipate that UiPath Inc. will post -0.04 EPS for the current year.

Insider Buying and Selling

In other UiPath news, CFO Ashim Gupta sold 16,000 shares of the stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $22.84, for a total value of $365,440.00. Following the completion of the transaction, the chief financial officer now directly owns 87,505 shares in the company, valued at $1,998,614.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 72,000 shares of company stock worth $1,591,360 in the last ninety days. 31.03% of the stock is owned by insiders.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.